{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.50","upperLimit":"61.44","value":"48.4"},{"groupId":"OG001","lowerLimit":"6.76","upperLimit":"93.24","value":"50.0"},{"comment":"N/A=NE=not estimable, because of insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG003","lowerLimit":"6.30","upperLimit":"38.08","value":"18.5"},{"groupId":"OG004","lowerLimit":"13.70","upperLimit":"78.80","value":"44.4"},{"groupId":"OG005","lowerLimit":"2.81","upperLimit":"60.01","value":"22.2"},{"groupId":"OG006","lowerLimit":"56.35","upperLimit":"91.03","value":"76.9"},{"groupId":"OG007","lowerLimit":"5.49","upperLimit":"57.19","value":"25.0"},{"groupId":"OG008","lowerLimit":"9.92","upperLimit":"65.11","value":"33.3"},{"groupId":"OG009","lowerLimit":"13.70","upperLimit":"78.80","value":"44.4"},{"groupId":"OG010","lowerLimit":"6.06","upperLimit":"36.89","value":"17.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"28"}],"units":"Participants"}],"description":"Included were participants with confirmed PR or CR or Stable Disease (SD) that had lasted at least 6 months according to RECIST v1.1 or confirmed CR, PR, VGPR, sCR or SD for at least 6 months according to IMWG criteria. RECIST v1.1: PR: \\>/= 30% decrease in the sum of diameters of target lesions; CR: disappearance of all target lesions; SD: not meeting criteria for CR, PR or progressive disease (PD). IMWG: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\</= 5% plasma cells in bone marrow; PR: \\>/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>/= 90% or to \\<200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>/= 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow; SD: not meeting criteria for CR, VGPR, PR or PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"OG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"OG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"OG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"OG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"OG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"OG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"OG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"OG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"OG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Percentage of Participants With Confirmed Clinical Benefit","type":"SECONDARY","unitOfMeasure":"percentage of participants"}